Scancell Holdings plc (LON:SCLP – Get Free Report) hit a new 52-week high on Monday . The company traded as high as GBX 12.34 and last traded at GBX 12.25, with a volume of 3539873 shares changing hands. The stock had previously closed at GBX 11.25.
Scancell Stock Performance
The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The company has a 50 day simple moving average of GBX 9.97 and a 200-day simple moving average of GBX 9.92. The firm has a market cap of £127.13 million, a PE ratio of -9.72 and a beta of 0.35.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Featured Stories
- Five stocks we like better than Scancell
- A month before the crash
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Trump’s Hand-Written Letter Will Shock his Haters
- The $100 Trillion AI Story No One Is Telling You
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
